B of A Securities Maintains Buy on BioXcel Therapeutics, Lowers Price Target to $7
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Geoff Meacham maintains a Buy rating on BioXcel Therapeutics (BTAI) but lowers the price target from $8 to $7.
March 13, 2024 | 2:32 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
B of A Securities maintains a Buy rating on BioXcel Therapeutics but lowers the price target from $8 to $7.
While the maintenance of a Buy rating indicates continued confidence in the company's potential, the reduction in price target suggests a tempered outlook on its short-term price performance. This mixed signal could lead to neutral market reaction in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100